Literature DB >> 10325919

Avidity of anti-P aeruginosa antibodies during chronic infection in patients with cystic fibrosis.

O Ciofu1, T D Petersen, P Jensen, N Høiby.   

Abstract

BACKGROUND: In order to study the impact on the lung function of patients with cystic fibrosis of the avidity of antipseudomonal antibodies, the avidity of antibodies against the chromosomal beta-lactamase of Pseudomonas aeruginosa (a beta ab) and against the 60-65 kDa heat shock protein of P aeruginosa (anti-GroEL) were measured in serum samples collected longitudinally during chronic infection with P aeruginosa from a group of patients with poor and good lung function.
METHODS: The thiocyanate elution method in which the molarity of potassium thiocyanate required to elute 50% bound antibody under conditions of antigen excess in ELISA was used to measure the relative avidity.
RESULTS: All patients developed increasing levels of a beta ab and anti-GroEL antibodies during the follow up period but no maturation of the avidity of these antibodies was observed. In patients with good lung function the avidity of a beta ab was higher than in patients with poor lung function (p = 0.018). No significant difference in the avidity of the anti-GroEL antibodies was observed between the two groups of patients.
CONCLUSION: In patients with cystic fibrosis a high avidity of a beta ab could contribute to a more efficient inhibition of the beta-lactamase by these antibodies, resulting in the better lung function seen in this group. The immunopathological implication of the failure in avidity maturation of antibodies in chronic infection is discussed.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10325919      PMCID: PMC1745423          DOI: 10.1136/thx.54.2.141

Source DB:  PubMed          Journal:  Thorax        ISSN: 0040-6376            Impact factor:   9.139


  19 in total

1.  Human constant regions influence the antibody binding characteristics of mouse-human chimeric IgG subclasses.

Authors:  N McCloskey; M W Turner; P Steffner; R Owens; D Goldblatt
Journal:  Immunology       Date:  1996-06       Impact factor: 7.397

2.  Antibodies of different human IgG subclasses show distinct patterns of affinity maturation after immunization with keyhole limpet haemocyanin.

Authors:  M E Devey; K M Bleasdale-Barr; P Bird; P L Amlot
Journal:  Immunology       Date:  1990-06       Impact factor: 7.397

3.  Serotype-specific serum IgG antibodies to lipopolysaccharides of Pseudomonas aeruginosa in cystic fibrosis: correlation to disease, subclass distribution, and experimental protective capacity.

Authors:  U B Schaad; A B Lang; J Wedgwood; U Buehlamnn; E Fuerer
Journal:  Pediatr Res       Date:  1990-05       Impact factor: 3.756

4.  Quantitative analysis of the IgG and IgG subclass immune responses to chromosomal Pseudomonas aeruginosa beta-lactamase in serum from patients with cystic fibrosis by western blotting and laser scanning densitometry.

Authors:  T D Petersen; O Ciofu; T Pressler; B Giwercman; S S Pedersen; N Høiby
Journal:  Thorax       Date:  1996-07       Impact factor: 9.139

5.  The functional affinities of antibodies of different IgG subclasses to dietary antigens in mothers and their babies.

Authors:  M E Devey; S Beckman; D M Kemeny
Journal:  Clin Exp Immunol       Date:  1993-10       Impact factor: 4.330

6.  Affinity constants of naturally acquired and vaccine-induced anti-Pseudomonas aeruginosa antibodies in healthy adults and cystic fibrosis patients.

Authors:  U Bruderer; S J Cryz; U B Schaad; M Deusinger; J U Que; A B Lang
Journal:  J Infect Dis       Date:  1992-08       Impact factor: 5.226

7.  Effect of high-affinity anti-Pseudomonas aeruginosa lipopolysaccharide antibodies induced by immunization on the rate of Pseudomonas aeruginosa infection in patients with cystic fibrosis.

Authors:  A B Lang; U B Schaad; A Rüdeberg; J Wedgwood; J U Que; E Fürer; S J Cryz
Journal:  J Pediatr       Date:  1995-11       Impact factor: 4.406

8.  Antibodies against Pseudomonas aeruginosa chromosomal beta-lactamase inpatients with cystic fibrosis are markers of the development of resistance of P. aeruginosa to beta-lactams.

Authors:  O Ciofu; B Giwercman; J Walter-Rasmussen; T Pressler; S S Pedersen; N Høiby
Journal:  J Antimicrob Chemother       Date:  1995-02       Impact factor: 5.790

9.  Correlation between specific IgG subclass antibodies to Pseudomonas aeruginosa and opsonic activity in serum from patients with cystic fibrosis.

Authors:  T Pressler; E T Jensen; F Espersen; S S Pedersen; N Høiby; C Koch
Journal:  Pediatr Pulmonol       Date:  1994-01

10.  Complement deposition by antibodies to Pseudomonas aeruginosa mucoid exopolysaccharide (MEP) and by non-MEP specific opsonins.

Authors:  G B Pier; M Grout; D Desjardins
Journal:  J Immunol       Date:  1991-09-15       Impact factor: 5.422

View more
  6 in total

Review 1.  Applying insights from biofilm biology to drug development - can a new approach be developed?

Authors:  Thomas Bjarnsholt; Oana Ciofu; Søren Molin; Michael Givskov; Niels Høiby
Journal:  Nat Rev Drug Discov       Date:  2013-10       Impact factor: 84.694

Review 2.  Recent developments for Pseudomonas vaccines.

Authors:  Anurag Sharma; Anja Krause; Stefan Worgall
Journal:  Hum Vaccin       Date:  2011-10-01

Review 3.  Pseudomonas aeruginosa Biofilms: Host Response and Clinical Implications in Lung Infections.

Authors:  Nicholas M Maurice; Brahmchetna Bedi; Ruxana T Sadikot
Journal:  Am J Respir Cell Mol Biol       Date:  2018-04       Impact factor: 6.914

4.  Host response to Staphylococcus aureus cytotoxins in children with cystic fibrosis.

Authors:  Ashley D Chadha; Isaac P Thomsen; Natalia Jimenez-Truque; Nicole R Soper; Lauren S Jones; Andrew G Sokolow; Victor J Torres; C Buddy Creech
Journal:  J Cyst Fibros       Date:  2016-01-25       Impact factor: 5.482

5.  X-ray Irradiated Vaccine Confers protection against Pneumonia caused by Pseudomonas aeruginosa.

Authors:  Yanyan Li; Zhenling Wang; Xiaoxiao Liu; Jianying Tang; Bin Peng; Yuquan Wei
Journal:  Sci Rep       Date:  2016-02-16       Impact factor: 4.379

6.  Recombinant Pseudomonas Bionanoparticles Induce Protection against Pneumonic Pseudomonas aeruginosa Infection.

Authors:  Peng Li; Xiuran Wang; Xiangwan Sun; Jesse Cimino; Ziqiang Guan; Wei Sun
Journal:  Infect Immun       Date:  2021-07-26       Impact factor: 3.609

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.